Stockscreener 앱 받기
1.19
4.03%
-0.05
시장 영업 전:
1.22
0.03
+2.52%
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Analysts Offer Predictions for Cabaletta Bio FY2029 Earnings - Defense World
FY2025 EPS Forecast for Cabaletta Bio Raised by Analyst - Defense World
Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat
Kaskela Law LLC Announces Stockholder Investigation of Cabaletta Bio, Inc.CABA - ACCESS Newswire
Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline - Investing.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World
Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from Guggenheim - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Posts Earnings Results, Meets Expectations - MarketBeat
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Meets Estimates - MarketBeat
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN
Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from HC Wainwright - Defense World
Cabaletta Bio’s (CABA) “Buy” Rating Reaffirmed at Guggenheim - Defense World
Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com Australia
Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa
Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com
UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener
Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks
Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada
Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com India
BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cabaletta Bio, Inc. SEC 10-K Report - TradingView
Cabaletta Bio Reports Clinical Wins in Multiple Diseases, Maintains Strong Cash Position - Stock Titan
Bank of New York Mellon Corp Sells 16,945 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline By Investing.com - Investing.com South Africa
Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline - Investing.com Australia
Are Value Hunters Buying Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register
Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat
Cellares and Cabaletta Bio Complete Manufacturing Technology Adoption Program - Genetic Engineering and Biotechnology News
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire
Major Breakthrough: Cellares Successfully Automates Multi-Batch CAR T Production for 260,000 Patients - Stock Titan
Cabaletta Bio Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $22.71 - MarketBeat
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) Target Price at $22.71 - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN
1.23%
1.63%
자본화:
|
볼륨(24시간):